# Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults

> **NCT00746798** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 479 (actual)

## Conditions studied

- West Nile Fever

## Interventions

- **BIOLOGICAL:** ChimeriVax-WN02 vaccine
- **BIOLOGICAL:** ChimeriVax-WN02 vaccine
- **BIOLOGICAL:** ChimeriVax-WN02 vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00746798
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-06
- **Final completion:** 2009-12
- **Target enrollment:** 479 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00746798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00746798, "Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00746798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*